NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BTIG Downgrades Neogenomics (NEO) to Neutral
July 27, 2016 7:34 AM EDTBTIG downgraded Neogenomics (NASDAQ: NEO) from Buy to Neutral and removed its price target. Analyst Sean Lavin sees less compelling risk reward.
"Shares have risen 70% in less than a year. Our Buy thesis had been predicated on continued share gains, stable reimbursement, and... More
NeoGenomics (NEO) Tops Q2 EPS by 1c
July 26, 2016 8:18 AM EDTNeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $63.1 million versus the consensus estimate of $61.07 million.
For earnings history and earnings-related data on NeoGenomics (NEO) click here.
... More